TheraSphere™ Y-90 Glass Microspheres

Dosage and administration

Deliver a proven dose, any day of the week

Any Day Dosing enables more options to treat with TheraSphere by expanding available treatment days throughout the week with an additional calibration day. No compromises, no added products or processes. The same TheraSphere — ready when you are.

Available exclusively on TheraSphere 360^TM, Any Day Dosing makes it easier to treat with the dose you want, providing more options to follow Dosimetry Steering Committee recommended treatment days.¹ Dose confidently and see reproducible results backed by data.

Watch the 45-second video

Mechanism of action = radiation

TheraSphere is uniquely engineered to have unmatched radiation per microsphere (RPM), maximizing lethal hits to tumor DNA and driving tumor cell death.

TheraSphere Y-90 Glass Microsphere

Radiation is embedded within the glass matrix, providing greater RPM

Y-90 Resin Microsphere

Radiation is only coated onto the surface area of the resin sphere,² limiting RPM

Watch TheraSphere mechanism of action explained

High RPM effectively drives dose and reproducible outcomes

Trials using TheraSphere's high RPM consistently demonstrate effective dose delivery, higher rates of tumor response, and complete pathologic necrosis (CPN).

TheraSphere glass maintains a higher RPM over time.

TheraSphere is the only radiation therapy with Level 1 randomized data to demonstrate efficacy in large liver tumors (mean tumor size of 10.5 cm)⁴ while also validating reproducible dosimetry planning with Simplicit90Y™ Personalized Dosimetry Software.⁹

Confidently dose during recommended treatment days while maintaining a good patient safety profile

Contemporary dosing recommendations below from an international multi-disciplinary working group were driven by TheraSphere landmark studies and advancing Y-90 techniques to improve outcomes. Recommendations include:

Five clinical scenarios (curative and palliative intent) to facilitate standardized personalized treatment to improve outcomes
Targeted absorbed dose in selective treatment of ≥ 400 Gy for complete pathologic necrosis radiation (single compartment)
Tumor absorbed dose of ≥ 205 Gy (> 250 Gy where possible) and normal absorbed dose in the perfused liver of ≤ 120 Gy in patients with ≥ 30% hepatic reserve (multi-compartment)

See the 5 clinical scenarios

Intended indications and use details

TheraSphere indications, safety, and warnings

Doses comprised of fewer spheres and higher RPM spare more normal tissue

Pre-clinical study using TheraSphere Y-90 Glass Microspheres confirmed treatments at or before 8 days post-calibration decreases normal liver toxicity.¹⁰

4 days post calibration: more healthy tissue spared with higher RPM and fewer spheres. 12 days post calibration: more healthy tissue exposed with lower RPM and more spheres.

Reimbursement

Find coding and economic resources for health care practitioners and their partners.

See reimbursement resources

References

Salem, R., Padia, S.A., Lam, M. et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 50, 328 -343 (2023). https://doi.org/10.1007/s00259-022-05956-w
Grosser OS, Ruf J, Pethe A, Kupitz D, Wissel H, Benckert C, Pech M, Ricke J, Amthauer H. Urinary Excretion of Yttrium-90 after Radioembolization with Yttrium-90-Labeled Resin-based Microspheres. Health Phys. 2018 Jan;114(1):58-63. doi: 10.1097/HP.0000000000000734. PMID: 29049048.
Radiation per microsphere (RPM) is a number that refers to the specific activity (SA) of a microsphere (Bq/Sphere). The RPM for TheraSphere is calculated based on targeted values and process means. Actual RPM can vary between microspheres. All numbers as of Noon Eastern Time. Ref Technical Report 97124387.
TheraSphere™ Y-90 Glass Microspheres DOSISPHERE-01 Study. Data on file.
TheraSphere™ Y-90 Glass Microspheres RASER Study. Data on file.
TheraSphere™ Y-90 Glass Microspheres LEGACY Study. Data on file.
TheraSphere™ Y-90 Glass Microspheres TARGET Study. Data on file.
Montazeri SA, De la Garza-Ramos C, Lewis AR, Lewis JT, LeGout JD, Sella DM, Paz-Fumagalli R, Devcic Z, Ritchie CA, Frey GT, Vidal L, Croome KP, McKinney JM, Harnois D, Krishnan S, Patel T, Toskich BB. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3892-3897. doi: 10.1007/s00259-022-05776-y. Epub 2022 Apr 20. PMID: 35441860.
Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0.
Pasciak, A. S., Abiola, G., Liddell, R. P., Crookston, N., Besharati, S., Donahue, D., Thompson, R. E., Frey, E., Anders, R. A., Dreher, M. R., & Weiss, C. R. (2019). The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 816–827. https://doi.org/10.1007/s00259-019-04588-x.